John Sonnier

In a report published Friday, William Blair & Company analyst John Sonnier reiterated an Outperform rating on Nektar Therapeutics (NASDAQ: NKTR). In the report, William Blair & Company noted, “Although NKTR-181 demonstrated analgesic properties in the Phase II trial, we acknowledge the...

William Blair & Company analysts John Sonnier, Timothy Lugo and Karen Jay maintained their Outperform rating for shares of Nektar Therapeutics (Nasdaq: NKTR). The analysts mentioned the many products in the company's pipeline and its strong balance sheet as reasons for their positive rating for...